Key Details
Price
$6.88Annual ROE
-21.71%Beta
1.63Events Calendar
Next earnings date:
Apr 25, 2025Recent quarterly earnings:
Jan 9, 2025Recent annual earnings:
Apr 25, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers.
We have put together a list of the 15 healthcare stocks that are performing exceptionally well in 2025. In this article, we will examine how Accolade Inc (NASDAQ:ACCD) compares to other healthcare stocks. The healthcare industry is recovering in 2025 after two years of poor performance.
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.
Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Accolade, Inc. is a promising buy due to tax loss season, with potential for a January recovery and long-term growth prospects. The stock's significant drop is attributed to IPO fallout and an overreaction to a minor revenue guidance decline. Its stock trades at a significant discount to its peers despite growing faster than all but one.
Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days.
FAQ
- What is the ticker symbol for Accolade?
- Does Accolade pay dividends?
- What sector is Accolade in?
- What industry is Accolade in?
- What country is Accolade based in?
- When did Accolade go public?
- Is Accolade in the S&P 500?
- Is Accolade in the NASDAQ 100?
- Is Accolade in the Dow Jones?
- When was Accolade's last earnings report?
- When does Accolade report earnings?
- Should I buy Accolade stock now?